A superantigen-based MHC class II targeted cancer immunotherapy for the treatment of acute myeloid leukemiaNathan G. Dolloff(Io Therapeutics (United States)), Kathleen Klinzing(Medical University of South Carolina)Research SquareApril 18, 202510.21203/rs.3.rs-6307085/v1Cited by 0SaveCiteExport RISWatch citationsRelated PapersPharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma|Biomolecules|2025|0A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia|Blood Cancer Journal|2025|0